Who we are

ECELLFRANCE is the French Research Infrastructure for mesenchymal stem cell (MSC)-based therapies.

Its mission is to develop cellular therapies based on the use of adult mesenchymal stem cells (MSC). These therapies aim to regenerate damaged tissues in many age-related pathologies and chronic inflammatory diseases currently without curative treatment, and are therefore a major goal in medicine.


The research infrastructure brings together key national actors in an integrated governance with the aim of enabling partners and teams requesting our support to become European leaders in their field of competence.


Since its creation in 2012, ECELLFRANCE has been involved in over 20 national and European research & innovation programs in cell-based therapy.

It brings together:
  • State-of-the-art Advanced Therapy Medicinal Products (ATMP) production platforms
  • Immunomonitoring and quality control platforms
  • Research teams with expertise on translational research in cell therapy
  • Clinical research teams to cover phase I and II clinical studies
In the field of:
  • Osteoarticular diseases
  • Autoimmune diseases
  • Cutaneous conditions
  • Ischemia
  • Stroke and neurological disorders





- 7 sites
- 57 research scientists (without counting clinical staff)
- 11 technological platforms :

  • Preclinical (3)
  • Production ATMP (5)
  • Quality control/safety/potency (1)
  • Immunomonitoring (2)

- 7 gouvernemental research organisations involved
- 9 National and European clinical programs running in 2018

Coordination : Université de Montpellier
Coordinator : Christian Jorgensen
Project manager : Gautier Robin

"Each site is associated with specific activities, technological platforms, and clinical expertise"

ECELLFrance clinical expertise in MSC therapy investigations include: osteoarticular conditions, cutaneous conditions, ischemia, cerebrovascular disorders, immunological disorders and alloreactivity.


ECELLFRANCE is open to academics and industrials requesting support for their pre-clinical and/or clinical programs in the field of cell-based therapies. The infrastructure provides services covering the entire MSC-based production and development pipeline including:

- Project validation - Production of ATMP - Immunomonitoring
- Preclinical studies

- Safety and potency tests


- Regulatory support

- Phase I and II clinical trials


Full service offering available here



Brochure available here